恒瑞医药：两款产品获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, marking a significant step in the development of innovative cancer treatments [1] Group 1: Product Development - HRS-4357 injection is a first-class radioactive therapy drug developed by the company, which will now undergo clinical trials for a new indication in combination with HRS-5041 for treating prostate cancer patients who are positive for prostate-specific membrane antigen (PSMA) [1] - HRS-5041 is a novel, efficient, and selective ARPROTAC small molecule developed by the company, aimed at treating prostate cancer [1] - There are currently no similar products approved for marketing in both domestic and international markets, indicating a unique position for the company's offerings [1]